When Twin came out of stealth in January 2024, AI agents were more of a theoretical concept than a reality. Today, the ...
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback